pEXO 001
Alternative Names: pEXO-001Latest Information Update: 25 Apr 2023
At a glance
- Originator Celularity
- Class Antirheumatics; Exosome therapies
- Mechanism of Action Exosome replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 11 Apr 2023 Preclinical trials in Osteoarthritis in USA (Parenteral) (Celularity pipeline, April 2023)
- 11 Apr 2023 Celularity plans an IND-enabling studies for Osteoarthritis (Celularity pipeline, April 2023)
- 04 Aug 2022 Celularity files for patent protection with USPTO for compositions and Methods of placenta-derived adherent cell exosomes in USA